By Katherine Hamilton
Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments.
The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier.
Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said.
Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023.
The New Haven, Conn. company did not share revenue data, in keeping with previous quarters.
Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio.
Trevi said it completed enrollment in February for the Phase 2b Coral trial in idiopathic pulmonary fibrosis patients with chronic cough, and expects topline data in the second quarter of 2025.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 18, 2025 16:17 ET (20:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.